MiNK Therapeutics/$INKT
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
- Ticker
- $INKT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 15
- Headquarters
- New York, United States
- Website
- minktherapeutics.com
INKT Metrics
BasicAdvanced
$52M
-
-$2.40
0.49
-
Price and volume
Market cap
$52M
Beta
0.49
52-week high
$16.93
52-week low
$8.48
Average daily volume
15K
Financial strength
Current ratio
1.228
Quick ratio
1.164
Profitability
EBITDA (TTM)
-11.833
Management effectiveness
Return on assets (TTM)
-123.84%
Return on equity (TTM)
57.94%
Valuation
Price to book
-3.71
Price to tangible book (TTM)
-3.71
Price to free cash flow (TTM)
-7.094
Free cash flow yield (TTM)
-14.10%
Free cash flow per share (TTM)
-1.441
Growth
Earnings per share change (TTM)
-15.69%
3-year earnings per share growth (CAGR)
-32.07%
What the Analysts think about INKT
Analyst ratings (Buy, Hold, Sell) for MiNK Therapeutics stock.
Analyst projections of the future price of MiNK Therapeutics stock.
INKT Financial Performance
Revenues and expenses
INKT Earnings Performance
Company profitability
Upcoming events
No upcoming events
INKT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.